Recent Updates
Recently added Catalysts
JSPR Negative Sentiment

JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics Investors to Contact the Firm Regarding Class Action Lawsuit

Key Takeaway: A class action lawsuit has been initiated against Jasper Therapeutics, Inc. by the law firm Bragar Eagel & Squire on behalf of investors. The lawsuit alleges that the company made materially false and misleading statements regarding its business operations and compliance policies from November 30, 2023, to July 3, 2025. Specific concerns include failures in ensuring third-party manufacturers were compliant with necessary regulations, which may compromise clinical trial outcomes and financial projections. Investors are encouraged to contact the firm for more information and to discuss potential claims.
Price reaction · baseline $2.51 (2025-10-20 close) · hit after-hours · clean, no other JSPR news in the window
day 0 close · peak
+1.2%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Jasper Therapeutics for misleading statements.
  • Allegations include failure to disclose compliance issues with third-party manufacturers.
  • Increased risk of negative impact on clinical trial results and commercial prospects.
  • Concerns regarding financial outlook overstated due to management's misrepresentation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
7.8%
average across 5 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
Isradipine
Phase 1 · Nicotine Dependence

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ:JSPR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”).
Investors have until November 18, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Jasper shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

Who should contact Bragar Eagel & Squire regarding Jasper losses?

Investors who purchased Jasper securities between November 30, 2023, and July 3, 2025, should contact them.

What is the deadline to apply as lead plaintiff in the Jasper lawsuit?

The deadline to apply to be lead plaintiff is November 18, 2025.

What allegations are made in the Jasper lawsuit?

The lawsuit alleges Jasper made misleading statements about its operations and compliance.

How can investors get more information about the lawsuit?

Investors can contact Brandon Walker or Marion Passmore via phone or email for details.

Is there a cost to consult with Bragar Eagel & Squire?

There is no cost or obligation to consult with Bragar Eagel & Squire.

Last updated: Oct 21, 2025